TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
IMVT

Immunovant Inc

Healthcare · Biotechnology

37.00$ -1.9% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

Immunovant Inc (IMVT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 7.1 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement IMVT
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
0.0 0.0 1.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 7.1 7.1
0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
-0.3 -0.1 1.4 -0.1 -0.1 -0.1 0.1 -0.1 -0.1 -0.1 7.1
48 48 66 75 97 95 94 101 114 99 142 143 498
14 13 15 19 18 20 20 26 18 15 17 18 68
62 62 81 94 116 114 114 127 132 114 160 160 566
-62 -62 -81 -94 -116 -114 -114 -127 -132 -114 -160 -153 -559
-58 -52 -75 -87 -109 -111 -106 -120 -126 -109 -151 -153 -539
0.5 -0.1 0.2 0.1 0.1 0.2 0.6 0.9 0.6 1.6 -2.8
-59 -51 -75 -87 -109 -111 -106 -121 -127 -111 -148 -153 -538
-58 -51 -75 -87 -109 -111 -106 -120 -126 -109 -151 -153 -539

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?